Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia.

Hui WeiYing WangRobert Peter GaleDong LinChunlin ZhouBingcheng LiuShaowei QiuRunxia GuYan LiXingli ZhaoShuning WeiBenfa GongKaiqi LiuXiaoyuan GongYuntao LiuGuangji ZhangZhen SongYang WangWei LiYingchang MiJianxiang Wang

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Induction therapy with intermediate-dose cytarabine with daunorubicin and omacetaxine mepesuccinate increases DFS and survival in persons with AML ages 15-55 years compared with conventional-dose cytarabine.See related commentary by Watts and Bradley, p. 3073.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
high dose
low dose
mesenchymal stem cells
acute lymphoblastic leukemia